Pneumocystis jirovecii Pneumonia in Patients Treated for Solid Organ Malignancy

REFERENCES

1. 1.↵
   1. Thomas CF Jr.,
   2. Limper AH

   . Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298-308. doi: 10.1038/nrmicro1621

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Stern A,
   2. Green H,
   3. Paul M,
   4. Vidal L,
   5. Leibovici L

   . Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;2014(10):CD005590. doi: 10.1002/14651858.CD005590.pub3

   OpenUrlCrossRef
3. 3.↵
   1. Jeon CH,
   2. Kim SH,
   3. Kim S,
   4. Bae M,
   5. Lee SJ,
   6. Lim S

   . Pneumocystis jirovecii pneumonia in patients with solid malignancies: a retrospective study in two hospitals. Pathogens. 2022;11(10):1169. doi: 10.3390/pathogens11101169

   OpenUrlCrossRef
4. 4.↵
   1. Citron ML,
   2. Berry DA,
   3. Cirrincione C,
   4. et al.

   Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 [published correction appears in J Clin Oncol. 2003 Jun 1;21(11):2226]. J Clin Oncol. 2003;21(8):1431-1439. doi: 10.1200/JCO.2003.09.081

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Waks AG,
   2. Tolaney SM,
   3. Galar A,
   4. et al.

   Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015;154(2):359-367. doi: 10.1007/s10549-015-3573-2

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Taplitz RA,
   2. Kennedy EB,
   3. Bow EJ,
   4. et al.

   Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043-3054. doi: 10.1200/JCO.18.00374

   OpenUrlCrossRefPubMed